Source-grounded facts extracted from Cencora, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Werner Baumann was elected as Director at Cencora, Inc..
“On August 9, 2023, the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”) elected Werner Baumann, 60, and Lauren Tyler, 61, to serve on the Board, effective October 1, 2023.”
Cencora, Inc. reported fiscal year 2023 third quarter ended June 30, 2023 results: revenue $66.9B, net income $480M, EPS $2.35. Guidance raised.
“Third Quarter Fiscal Year 2023 Summary Results GAAP Adjusted (Non-GAAP) Revenue $66.9B $66.9B Gross Profit $2.3B $2.2B Operating Expenses $1.6B $1.4B Operating Income $670M $822M Interest Expense, Net $58M $58M Effective Tax Rate 21.3% 21.5% Net Income Attributable to AmerisourceBergen Corporation $480M $596M Diluted Earnings Per Share $2.35 $2.92”
Cencora, Inc. entered into Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC valued at approximately $50 million (effective 2023-06-15).
“On June 15, 2023, AmerisourceBergen Corporation (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase 275,984 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) directly from the Selling Stockholder (the “Repurchase”).”
Cencora, Inc. entered into Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC valued at approximately $50 million (effective 2023-05-11).
“On May 11, 2023, AmerisourceBergen Corporation (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase 292,792 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), directly from the Selling Stockholder (the “Repurchase”). The Repurchase was consummated on May 15, 2023. The aggregate price paid by the Company in the Repurchase was approximately $50 million.”
Cencora, Inc. amended Nineteenth Amendment to Amended and Restated Receivables Purchase Agreement with MUFG Bank, Ltd., as administrator (effective 2023-05-03).
“On May 3, 2023, subsidiaries of AmerisourceBergen Corporation (the “Company”) entered into a Nineteenth Amendment to Amended and Restated Receivables Purchase Agreement (the “Receivables Amendment”), among Amerisource Receivables Financial Corporation (“ARFC”), as seller, AmerisourceBergen Drug Corporation (“ABDC”), as servicer, the Purchaser Agents and Purchasers party thereto, and MUFG Bank, Ltd., as administrator.”
Cencora, Inc. reported fiscal 2023 results: EPS 11.70 to 11.90. Guidance raised.
“Adjusted diluted EPS guidance has been raised from the previous range of $11.50 to $11.75 to a range of $11.70 to $11.90.”
Cencora, Inc. reported fiscal quarter ended March 31, 2023 results: revenue 63.5 billion, net income 435M, EPS 2.13.
“--- EX-99.1 (EX-99.1) --- AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2023 SECOND QUARTER RESULTS Revenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50 Adjusted Diluted EPS Guidance Range”
Cencora, Inc. shareholders rejected Shareholder Proposal Regarding Shareholder Ratification of Termination Pay at the 2023-03-09 meeting.
“Item 5 - Shareholder Proposal Regarding Shareholder Ratification of Termination Pay. The Company’s shareholders did not approve this item. The voting results were as follows: For Against Abstentions Broker Non-Votes 15,064,251 160,009,226 727,198 10,193,326”
Cencora, Inc. shareholders approved Advisory Vote on the Frequency of a Shareholder Vote on the Compensation of the Company’s Named Executive Officers at the 2023-03-09 meeting.
“Item 4 - Advisory Vote on the Frequency of a Shareholder Vote on the Compensation of the Company’s Named Executive Officers. The Company’s shareholders voted for holding an annual advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 173,594,566 85,242 1,839,786 281,081 10,193,326”
Cencora, Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2023-03-09 meeting.
“Item 3 - Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers. The Company’s shareholders approved this item. The voting results were as follows: For Against Abstentions Broker Non-Votes 167,879,511 7,418,048 503,116 10,193,326”
Cencora, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2023 at the 2023-03-09 meeting.
“Item 2 - Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2023. The Company’s shareholders approved this item. The voting results were as follows: For Against Abstentions Broker Non-Votes 175,918,757 9,856,170 219,074 N/A”
Cencora, Inc. shareholders approved Election of Directors at the 2023-03-09 meeting.
“Item 1 - Election of Directors. Each of the individuals listed below was elected by the Company’s shareholders to serve as a director until the 2024 Annual Meeting of Shareholders and until his or her successor is duly elected and qualified.”
Cencora, Inc. reported fiscal year 2023 first quarter ended December 31, 2022 results: revenue $62.8 billion, net income $480M, EPS $2.33. Guidance raised.
“AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023 first quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to $2.13 in the prior year first quarter.”
Michael J. Long departed as Director at Cencora, Inc..
“On January 23, 2023, two members of the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”), Jane E. Henney, M.D. and Michael J. Long, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 9, 2023 (the “Annual Meeting”).”
Jane E. Henney departed as Director at Cencora, Inc..
“On January 23, 2023, two members of the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”), Jane E. Henney, M.D. and Michael J. Long, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 9, 2023 (the “Annual Meeting”).”
Cencora, Inc. entered into Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC valued at approximately $200 million (effective 2022-12-08).
“On December 8, 2022, AmerisourceBergen Corporation (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase 1,211,534 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) directly from the Selling Stockholder (the “Repurchase”).”
Redonda G. Miller, M.D. was elected as Director at Cencora, Inc..
“On November 9, 2022, the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”) elected Redonda G. Miller, M.D., 56, to serve on the Board, effective January 1, 2023.”
Robert Mauch was appointed as Executive Vice President and Chief Operating Officer at Cencora, Inc..
“the sole purpose of this Amendment is to provide Mr. Mauch’s compensation in connection with his appointment as Executive Vice President and Chief Operating Officer.”
Cencora, Inc. entered into Underwriting Agreement with Walgreens Boots Alliance Holdings LLC and Morgan Stanley & Co. LLC (effective 2022-11-07).
“In connection with the Secondary Offering, on November 7, 2022, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with the Selling Stockholder and Morgan Stanley & Co. LLC (the “Underwriter”).”
Cencora, Inc. entered into Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC valued at $500,000,053.80 (effective 2022-11-06).
“On November 6, 2022, AmerisourceBergen Corporation (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase, directly from the Selling Stockholder, 3,234,153 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”).”
Cencora, Inc. reported the fiscal year ended September 30, 2022 results: revenue $238.6 billion, EPS Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03.
“Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03”
Cencora, Inc. reported the fiscal quarter ended September 30, 2022 results: revenue $61.2 billion, net income $295 million, EPS GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60.
“Revenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60”
Robert P. Mauch was appointed as Executive Vice President and Chief Operating Officer at Cencora, Inc..
“On November 3, 2022, AmerisourceBergen Corporation (the “Company”) announced the appointment of Robert P. Mauch as Executive Vice President and Chief Operating Officer effective October 1, 2022.”
Cencora, Inc. amended revolving credit with JPMorgan Chase Bank, N.A., as administrative agent at ranges from 80.5 basis points to 122.5 basis points over Term SOFR maturing October 27, 2027.
“The Revolving Credit Facility was amended and restated to extend the maturity date of the facility to October 27, 2027 and to make certain changes to effect a transition from the LIBOR interest rate benchmark to Term SOFR.”
Cencora, Inc. amended Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. (effective 2022-10-27).
“On October 27, 2022, AmerisourceBergen Corporation (the “Company”) and its subsidiaries BP Pharmaceuticals Laboratories Unlimited Company, Centaur Services Limited and Innomar Strategies Inc. entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) to amend and restate the Amended and Restated Credit Agreement, dated as of November 4, 2021, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, pursuant to which the Company and such subsidiaries obtained a senior unsecured multi-currency revolving credit facility (the “Revolving Credit Facility”).”
Elizabeth S. Campbell was appointed as Executive Vice President and Chief Legal Officer at Cencora, Inc..
“Effective September 1, 2021, Mr. Chou will be succeeded by Elizabeth S. Campbell, currently Senior Vice President and Deputy General Counsel, who will become Executive Vice President and Chief Legal Officer and a member of the Company’s Executive Management Committee.”
John G. Chou departed as Executive Vice President and Chief Legal Officer at Cencora, Inc..
“Executive Vice President and Chief Legal Officer John G. Chou has notified the Company of his plans to retire after a 19-year career with the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.